Terms: = Head and neck cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
65 results:
1. treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.
Augustyn K; Joseph J; Patel AB; Razmandi A; Ali AN; Tawbi HA
Melanoma Res; 2023 Oct; 33(5):406-416. PubMed ID: 37534686
[TBL] [Abstract] [Full Text] [Related]
2. Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
Novoplansky O; Shnerb AB; Marripati D; Jagadeeshan S; Abu Shareb R; Conde-López C; Zorea J; Prasad M; Ben Lulu T; Yegodayev KM; Benafsha C; Li Y; Kong D; Kuo F; Morris LGT; Kurth I; Hess J; Elkabets M
Mol Oncol; 2023 Dec; 17(12):2618-2636. PubMed ID: 37501404
[TBL] [Abstract] [Full Text] [Related]
3. Visfatin upregulates VEGF-C expression and lymphangiogenesis in esophageal cancer by activating mek1/2-ERK and NF-κB signaling.
Huang CL; Achudhan D; Liu PI; Lin YY; Liu SC; Guo JH; Liu CL; Wu CY; Wang SW; Tang CH
Aging (Albany NY); 2023 Jun; 15(11):4774-4793. PubMed ID: 37286356
[TBL] [Abstract] [Full Text] [Related]
4. Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.
Hicks HM; Pozdeyev N; Sams SB; Pugazhenthi U; Bales ES; Hofmann MC; McKenna LR; Schweppe RE
Mol Cancer Res; 2023 Sep; 21(9):867-880. PubMed ID: 37219859
[TBL] [Abstract] [Full Text] [Related]
5. MiR-942-5p inhibits tumor migration and invasion through targeting CST1 in esophageal squamous cell carcinoma.
Zhang L; Yu S; Yin X; Tu M; Cai L; Zhang Y; Yu L; Zhang S; Pan X; Huang Y
PLoS One; 2023; 18(2):e0277006. PubMed ID: 36848349
[TBL] [Abstract] [Full Text] [Related]
6. EBV LMP1-C terminal binding affibody molecule downregulates MEK/ERK/p90RSK pathway and inhibits the proliferation of nasopharyngeal carcinoma cells in mouse tumor xenograft models.
Guo Y; Kamara S; Zhang J; Wen H; Zheng M; Liu Y; Zhou L; Chen J; Zhu S; Zhang L
Front Cell Infect Microbiol; 2022; 12():1078504. PubMed ID: 36683690
[TBL] [Abstract] [Full Text] [Related]
7. Daurisoline suppresses esophageal squamous cell carcinoma growth in vitro and in vivo by targeting mek1/2 kinase.
Wang D; Zhang W; Zhang X; Li M; Wu Q; Li X; Zhao L; Yuan Q; Yu Y; Lu J; Zhao J; Dong Z; Liu K; Jiang Y
Mol Carcinog; 2023 Apr; 62(4):517-531. PubMed ID: 36645220
[TBL] [Abstract] [Full Text] [Related]
8. Involvement of AMPKα and MAPK-ERK/-JNK Signals in Docetaxel-Induced Human Tongue Squamous Cell Carcinoma Cell Apoptosis.
Su CC; Lin JW; Chang KY; Wu CT; Liu SH; Chang KC; Liu JM; Lee KI; Fang KM; Chen YW
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430348
[TBL] [Abstract] [Full Text] [Related]
9. Reiterative modeling of combined transcriptomic and proteomic features refines and improves the prediction of early recurrence in squamous cell carcinoma of head and neck.
Salehi A; Wang L; Coates PJ; Norberg Spaak L; Gu X; Sgaramella N; Nylander K
Comput Biol Med; 2022 Oct; 149():105991. PubMed ID: 36007290
[TBL] [Abstract] [Full Text] [Related]
10. Inhibition of angiogenesis and tumor progression of MK-0429, an integrin αvβ
Nakagawa T; Ohta K; Naruse T; Sakuma M; Fukada S; Yamakado N; Akagi M; Sasaki K; Niwata C; Ono S; Aikawa T
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3281-3292. PubMed ID: 35713706
[TBL] [Abstract] [Full Text] [Related]
11. Novel Therapeutics for Advanced Differentiated Thyroid cancer.
Lieberman L; Worden F
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):367-378. PubMed ID: 35662446
[TBL] [Abstract] [Full Text] [Related]
12. Dysregulation of CXCL14 promotes malignant phenotypes of esophageal squamous carcinoma cells via regulating SRC and EGFR signaling.
Guo J; Chang C; Yang LY; Cai HQ; Chen DX; Zhang Y; Cai Y; Wang JJ; Wei WQ; Hao JJ; Wang MR
Biochem Biophys Res Commun; 2022 Jun; 609():75-83. PubMed ID: 35421632
[TBL] [Abstract] [Full Text] [Related]
13. mek1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.
Prasad M; Zorea J; Jagadeeshan S; Shnerb AB; Mathukkada S; Bouaoud J; Michon L; Novoplansky O; Badarni M; Cohen L; Yegodayev KM; Tzadok S; Rotblat B; Brezina L; Mock A; Karabajakian A; Fayette J; Cohen I; Cooks T; Allon I; Dimitstein O; Joshua B; Kong D; Voronov E; Scaltriti M; Carmi Y; Conde-Lopez C; Hess J; Kurth I; Morris LGT; Saintigny P; Elkabets M
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35292516
[TBL] [Abstract] [Full Text] [Related]
14. Hyperactivation of MEK/ERK pathway by Ca
Najar MA; Aravind A; Dagamajalu S; Sidransky D; Ashktorab H; Smoot DT; Gowda H; Prasad TSK; Modi PK; Chatterjee A
Mol Carcinog; 2021 Nov; 60(11):769-783. PubMed ID: 34437731
[TBL] [Abstract] [Full Text] [Related]
15. A model of seven immune checkpoint-related genes predicting overall survival for head and neck squamous cell carcinoma.
Song D; Tian J; Han X; Li X
Eur Arch Otorhinolaryngol; 2021 Sep; 278(9):3467-3477. PubMed ID: 33449165
[TBL] [Abstract] [Full Text] [Related]
16. p-MEK expression predicts prognosis of patients with adenocarcinoma of esophagogastric junction (AEG) and plays a role in anti-AEG efficacy of Huaier.
Yuan L; Mo SW; Xu ZY; Lv H; Xu JL; Guo KB; Hu C; Wang XF; Chen GP; Qin JJ; Cheng XD
Pharmacol Res; 2021 Mar; 165():105411. PubMed ID: 33401002
[TBL] [Abstract] [Full Text] [Related]
17. BRAF
Traversi F; Stooss A; Dettmer MS; Charles RP
Thyroid; 2021 May; 31(5):787-799. PubMed ID: 33012268
[No Abstract] [Full Text] [Related]
18. Tumor microRNA-126 controls cell viability and associates with poor survival in patients with esophageal adenocarcinoma.
Toxopeus E; Lynam-Lennon N; Biermann K; Dickens G; de Ruiter PE; van Lanschot J; Reynolds JV; Wijnhoven B; O'Sullivan J; van der Laan L
Exp Biol Med (Maywood); 2019 Oct; 244(14):1210-1219. PubMed ID: 31390899
[TBL] [Abstract] [Full Text] [Related]
19. Exogenous Hydrogen Sulfide Regulates the Growth of Human Thyroid Carcinoma Cells.
Wu D; Li J; Zhang Q; Tian W; Zhong P; Liu Z; Wang H; Wang H; Ji A; Li Y
Oxid Med Cell Longev; 2019; 2019():6927298. PubMed ID: 31223424
[TBL] [Abstract] [Full Text] [Related]
20. KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid cancer.
Owen DH; Konda B; Sipos J; Liu T; Webb A; Ringel MD; Timmers CD; Shah MH
J Natl Compr Canc Netw; 2019 May; 17(5):409-413. PubMed ID: 31085763
[TBL] [Abstract] [Full Text] [Related]
[Next]
